SOM Biotech completes the recruitment process in the Phase IIb study of the treatment of chorea in Huntington’s disease

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed. After a a Phase IIa study where the Read more…

en_USEnglish
Skip to content